Recent news on Epoetin Alfa

MIRCERA Receives Positive Opinion in Europe for the Treatment of ...  -  25 May 2007
Juraforum.de,MIRCERA is the only drug to have compared itself inits registration program to three ESAs: epoetin alfa, beta anddarbepoetin alfa.

Aranesp® and Epoetin Alfa Do Not Increase Blood Clots in Ovarian ...  -  May 1, 2007
Cancer Consultants (press release),According to an article recently published in Gynecologic Oncology, use of Aranesp® (darbepoetin alfa) or epoetin alfa (Procrit® or Epogen®) does not appear

FDA issues approvable letter for Roche's Mircera  -  May 21, 2007
Pharma Times (subscription),...of the warning labels on Amgen's ESAs, Aranesp (darbepoetin alfa) and Epogen (epoetin alfa), as well as Johnson & Johnson's Procrit (also epoetin alfa).

Amgen shares slide yet again over Medicare coverage cuts  -  May 16, 2007
Pharma Times (subscription),...as well as Johnson & Johnson's Procrit (also epoetin alfa), the Centers for Medicare & Medicaid Services (CMS) has proposed limiting payments for the

Amgen and J&J hurt by FDA panel over anaemia drugs  -  May 11, 2007
Pharma Times (subscription),...alfa) and Epogen (epoetin alfa) and J& J's Procrit (also epoetin alfa) be contingent upon adding additional restrictions to the drugs' labels.

FDA Sounds Alert on Anemia Drugs  -  May 1, 2007
Journal of American Medical Association (subscription),The FDA warning applies specifically to darbepoetin alfa (Aranesp, made by Amgen Inc, Thousand Oaks, Calif) and epoetin alfa (Epogen, made by Amgen,

News For Your Web Site  -  May 21, 2007
dBusinessNews Newark (press release),It is also the only anemia therapy to have compared itself in clinical trials against all commercially available agents: epoetin alfa, epoetin beta and

Roche receives approvable letter for Mircera in the United States  -  May 22, 2007
PipelineReview.com (press release),It is also the only anaemia therapy to have compared itself in clinical trials against epoetin alfa, beta and darbepoetin alfa.

CMS Cites EPO's Bad Rap In Plan To Curtail Reimbursement  -  May 15, 2007
BioWorld Online,Amgen, of Thousand Oaks, Calif., makes all the products in question: Aranesp (darbepoetin alfa), Epogen (epoetin alfa) and Procrit (epoetin alfa).

Supreme Court turns down Amgen patent appeal  -  May 15, 2007
Pharma Times (subscription),The US Supreme Court says that it will not hear an appeal by Amgen relating to two patents covering Epogen (epoetin alfa), which relate to the composition

Addition of IV Iron to Treatment with Red Blood Cell Booster May ...  -  May 7, 2007
Cancer Consultants (press release),In cancer patients, use of red blood cell boosters such as Aranesp® (darbepoetin alfa) and Procrit® (epoetin alfa) has been shown to decrease the need for

Aranesp® Improves Hemoglobin Levels in Lung Cancer Patients  -  Apr 27, 2007
Cancer Consultants (press release),Medications such as Procrit® (epoetin alfa) and Aranesp® (darbepoetin alfa) stimulate the body to produce more red blood cells, ultimately reducing anemia

New anaemia med warnings  -  May 12, 2007
Health24.com,The drugs include darbepoetin (Aranesp) and epoetin alfa (Epogen and Procrit). They are genetically engineered versions of a natural protein, erythropoietin

Discovery Labs Reports First Quarter 2007 Financial Results  -  May 2, 2007
Primenewswire (press release),Mr. Amick enjoyed a highly successful 30-year career with Johnson & Johnson (J&J) where he led the launch of Procrit(r) (Epoetin alfa) and built J&J's

Affymax Announces Phase 2 Clinical Trial Results of Once-Per-Month ...  -  Apr 23, 2007
PharmaLive.com (press release),Similarly, the data in dialysis patients previously treated with three-times weekly Epoetin Alfa demonstrated that mean hemoglobin (Hgb) levels could be

Ortho Biotech Revises Prescribing Information for PROCRIT(R ...  -  Apr 3, 2007
Drug Newswire (press release),Located in Bridgewater, NJ, Ortho Biotech is an established market leader in Epoetin alfa therapy for anemia management. The company also markets treatments

Prospective Model Outlined Potential Time and Cost Savings of Once ...  -  Apr 24, 2007
PharmaLive.com (press release),The primary objective of this analysis was to evaluate time and associated in-center supply costs observed while administering epoetin alfa three times a

Aranesp linked to higher death rate in cancer trial  -  Apr 17, 2007
Pharma Times (subscription),In March, US regulators requested that new safety and dosage information should be added the labels of Amgen's Aranesp and Epogen (epoetin alfa) and Johnson

Amgen's First Quarter 2007 Revenue Increased 15 Percent to $3.7 ...  -  Apr 24, 2007
PharmaLive.com (press release),Sales of EPOGEN(R) (Epoetin alfa) increased 3 percent to $625 million in the first quarter of 2007 versus $604 million in the first quarter of 2006.

Affymax cites positive Hematide data  -  Apr 12, 2007
BusinessWeekThe study involved 165 patients who switched from a thrice-weekly treatment with Epoetin Alfa. Amgen Inc. and Johnson & Johnson both sell Epoetin Alfa drugs

Affymax (AFFY) Announces Results From Phase 2 Clinical Trial of ...  -  Apr 12, 2007
StreetInsider.com (subscription),The results from this maintenance-switch trial in patients previously treated with three-times weekly Epoetin Alfa (EPO) demonstrated that mean hemoglobin

The Top 14 Most Counterfeited Medications  -  Mar 28, 2007
ScienceBlogsEpogen (epoetin alfa - often used in the treatment of those with HIV, receiving chemotherapy, or with renal failure). 5. Lamisil (terbinafine - used in the

Aranesp(R) "145 Study" Shows No Difference In Survival In Patients ...  -  Apr 23, 2007
Medical News Today (press release),A higher incidence of deep venous thrombosis was documented in patients receiving Epoetin alfa who were not receiving prophylactic anticoagulation.

MIRCERA(R) Effective in Stabilising Haemoglobin Levels in Elderly ...  -  Apr 23, 2007
PR Newswire Brasil (liberação de imprensa),...in dialysis patients over and under 65 years of age who were successfully switched from the frequently administered agents, epoetin alfa and beta.

IV Iron Decreases Epoetin Dose Requirements and Improves ...  -  Apr 13, 2007
Cancer Consultants (press release),Recent FDA/ASH recommendations concerning the use of epoetin alfa suggest using lower target hemoglobin levels and lower doses to prevent some of the

Data Analyses Outline Efficacy and Safety of MIRCERA™ for the ...  -  Apr 13, 2007
WebWire (press release),This was an overview of six global studies in approximately 2400 patients that compared MIRCERA with epoetin alfa or beta and with darbepoetin alfa.

Data Analyses Outline Efficacy and Safety of MIRCERA(TM) for the ...  -  Apr 12, 2007
PR Newswire (press release),...once every four weeks in patients with or without congestive heart failure who were on dialysis and were directly converted from epoetin alfa or beta.

Mircera stabilizes Hb levels in elderly dialysis patients  -  Apr 23, 2007
Renal Business Today,...stable hemoglobin levels in dialysis patients over the age of 65 that were switched from the frequently administered agents epoetin alfa and beta.

MIRCERA(R) Effective in Stabilising Haemoglobin Levels in Elderly ...  -  Apr 23, 2007
Juraforum.de,...levels in dialysis patients over andunder 65 years of age who were successfully switched from thefrequently administered agents, epoetin alfa and beta.

Anemia After Kidney Transplant Worsens Outcomes  -  Apr 18, 2007
MedPage Today,Last month, the FDA issued a black box warning for erythropoiesis-stimulating agents, including darbepoetin alfa (Aranesp) and epoetin alfa (Epogen,

Affymax drug promising for dialysis anemia  -  Apr 12, 2007
United Press InternationalThe company said its open-label, "maintenance-switch" trial showed 165 patients who had been taking Epoetin Alfa three times a week, and switched to monthly

DNAPrint(TM) Genomics` Advancements in PT-401 and Statinome ...  -  Apr 5, 2007
MacReport (press release),In one study, PT-401 was shown to be more potent and longer acting than epoetin alfa, a form of recombinant human erythropoietin currently in the market for

In Brief  -  Apr 3, 2007
Nature.com (subscription),...as well as to Amgen's Epogen and New Brunswick, New Jersey-based Johnson & Johnson's Procrit (both drugs are epoetin alfa) and adjusted their labels.

Erythropoietin drugs: What to know about anemia-fighting medications  -  Mar 29, 2007
MayoClinic.comIncluded in the warning are darbepoetin alfa (Aranesp) and epoetin alfa (Epogen, Procrit). Here to answer some questions about erythropoietin and ESAs is

Market Report -- In Play (AFFY)  -  Apr 12, 2007
MSN MoneyThe results from this maintenance-switch trial in patients previously treated with three-times weekly Epoetin Alfa demonstrated that mean hemoglobin levels

Nephrogenic Fibrosing Dermopathy Associated With Exposure to ...  -  Apr 10, 2007
Journal of American Medical Association (subscription),The maximum erythropoietin (epoetin alfa) dose received during the preceding 6 months and the dose received at the time of disease detection (for

Epoetin Alfa May Decrease Survival in Anemic Patients with NSCLC  -  27 Mar 2007
Cancer Consultants (press release),Pre-operative epoetin alfa may be associated with a higher incidence of deep vein thrombosis when given without anticoagulation.

Ortho Biotech Revises Prescribing Information For PROCRIT ...  -  Mar 12, 2007
Medical News Today (press release),Ortho Biotech Products, LP, today revised the label for PROCRIT® (Epoetin alfa), acting upon guidance from the US Food and Drug Administration (FDA) to

Ortho Biotech Revises Prescribing Information for PROCRIT(R ...  -  Mar 9, 2007
PR Newswire (press release),About PROCRIT (Epoetin alfa) PROCRIT is approved for the treatment of anemia in patients with most types of cancer receiving chemotherapy, with chronic

Ortho Biotech Revises Prescribing Information for PROCRIT(R ...  -  Mar 9, 2007
PR Newswire (press release),Located in Bridgewater, NJ, Ortho Biotech is an established market leader in Epoetin alfa therapy for anemia management. The company also markets treatments

Ortho Biotech Revises Prescribing Information for PROCRIT(R ...  -  Mar 9, 2007
Earthtimes.orgBRIDGEWATER, NJ, March 9 -- Ortho Biotech Products, LP today revised the label for PROCRIT(R) (Epoetin alfa), acting upon guidance from the US Food and Drug

Amgen's Trial Of Vectibix Falls Short; ImClone Shares Benefit  -  Mar 25, 2007
BioWorld Online,The new warnings affected Aranesp (darbepoetin alfa), Epogen (epoetin alfa) and Epogen's counterpart, Procrit, which is marketed by New Brunswick,

Black Box Warning Ordered for Aranesp, Epogen, and Procrit  -  Mar 9, 2007
MedPage Today,Patients treated before surgery with epoetin alfa to reduce allogenic red blood cell transfusions had a higher incidence of deep vein thrombosis.

Black Box Warning for Erythropoiesis-Stimulating Agents  -  Mar 12, 2007
Medscape (subscription)Darbepoetin alfa and epoetin alfa are indicated for the treatment of CRF-related anemia, and chemotherapy-related anemia in patients with nonmyeloid

New Guidelines on the Use of Procrit® and Ananesp® Released by ASH ...  -  Mar 13, 2007
Cancer Consultants (press release),The American Society of Hematology (ASH) in collaboration with the Food and Drug Administration (FDA) has released new guidelines on the use of epoetin alfa

Amgen Announces Update To US Prescribing Information For Aranesp ...  -  Mar 12, 2007
Safety Online (press release),...a higher incidence of deep venous thrombosis was documented in patients receiving Epoetin alfa who were not receiving prophylactic anticoagulation.

Amgen, J&J warned by FDA over anaemia drug labelling  -  Mar 12, 2007
Pharma Times (subscription),...of Amgen's erythropoiesis-stimulating agents Aranesp (darbepoetin alfa) and Epogen (epoetin alfa) and Johnson & Johnson's Procrit (also epoetin alfa).

Ortho Biotech in Discussions with FDA Regarding Prescribing ...  -  Feb 28, 2007
PR Newswire (press release),These data may have an impact on labeling in other parts of the world for EPREX(R) (Epoetin alfa), which is marketed by Janssen-Cilag.

Revised Safety Information Approved for Aranesp, Epogen, and Procrit  -  Mar 13, 2007
Facts and Comparisons,The FDA has issued a public health advisory detailing new safety information for darbepoetin alfa (Aranesp) and epoetin alfa (Epogen and )

Reps. Dingell, Stupak Call on Amgen, Johnson & Johnson to Suspend ...  -  Mar 22, 2007
PharmaLive.com (press release),The anemia medications include Erythropoiesis-Stimulating Agents (ESAs), commonly known as EPO products, Epoetin alfa (marketed as Procrit, Epogen),

FDA cracks down on anemia-drug use  -  Mar 10, 2007
Los Angeles Daily News,The drugs are darbepoetin alfa, sold as Aranesp by Amgen, and epoetin alfa, sold as Epogen by Amgen and as Procrit by Johnson & Johnson.

New York Times: Doctors in Bed with Big Pharma  -  Mar 21, 2007
Newsinferno.com,...warning earlier this month about erythropoiesis-stimulating agents (ESAs), including darbepoetin alfa (Aranesp) and epoetin alfa (Epogen and Procrit).

Anemia drugs increase death risk  -  Mar 9, 2007
Food Consumer,The products are darbepoetin alfa and epoetin alfa. Darbepoetin alfa was approved for marketing on September 17, 2001 and is licensed and marketed by Amgen,

Toll from crash of team bus rises to seven  -  Mar 9, 2007
St. Petersburg Times,...been added to the labels of darbepoetin alfa, sold as Aranesp by Amgen, and epoetin alfa, sold as Epogen by Amgen and as Procrit by Johnson & Johnson.

FDA Issues "Black-Box" Warnings Against Three Anemia Drugs  -  Mar 9, 2007
All Headline NewsThe drugs affected, known as erythropoiesis-stimulating agents or ESAs, are darbepoetin alfa (brand name Aranesp) and two epoetin alfa brands (Epogen and

FDA Tightens Warnings on Anemia Drugs  -  Mar 9, 2007
Persian Journal,The drugs included in the new safety update are darbepoetin alfa (Aranesp) and epoetin alfa (Epogen and Procrit). These drugs are genetically engineered

FDA Strengthens Warning on Drugs prescribed for Anemia in Cancer ...  -  Mar 9, 2007
Cancer Focus,The drugs affected by the safety update are darbepoetin alfa (Aranesp) and epoetin alfa (Epogen and Procrit). The FDA and the manufacturer of these products

FDA Updates Safety for Anemia Erythropoiesis-Stimulating Drugs  -  Mar 9, 2007
Playfuls.com,...a statement announcing the strenghtening of safety-related information in the drugs darbepoetin alfa (Aranesp) and epoetin alfa (Epogen and Procrit).

Roche hurt by enrolment suspension in Mircera study  -  Feb 26, 2007
Pharma Times (subscription),...reflects growing safety concerns over the class of erythropoietin-based drugs such as Amgen Aranesp and Johnson & Johnson's Procrit (epoetin alfa).

FDA Issues Advisory Regarding Use of Red-blood Cell Boosters  -  Mar 12, 2007
Cancer Consultants (press release),Erythropoiesis-stimulating agents include Procrit® (epoetin alfa) and Aranesp® (darbepoetin alfa). In cancer patients, use of medications to treat anemia

FDA - Black Box Warning on Anemia Drugs Epogen Procrit and Aranesp ...  -  Mar 12, 2007
Best Syndication,The drugs are Erythropoiesis-Stimulating Agents (ESAs) and include darbepoetin alfa (Aranesp) and epoetin alfa (Epogen and Procrit).

FDA Strengthens Safety Information for Erythropoiesis-Stimulating ...  -  Mar 11, 2007
WebWire (press release),The drugs affected by the safety update are darbepoetin alfa (Aranesp) and epoetin alfa (Epogen and Procrit). (ESAs are genetically engineered forms of the

EPO Warning Nicks Amgen; Off-Label Risks Told Earlier  -  Mar 9, 2007
BioWorld Online,Epogen (epoetin alfa) and its counterpart Procrit, marketed by New Brunswick, NJ-based Johnson & Johnson, also are cleared for patients scheduled for major

FDA Warns of Serious Side Effects Related to Popular Anemia Drugs  -  Mar 9, 2007
Newsinferno.com,The warnings relate to darbepoetin alfa (Aranesp) and epoetin alfa (Epogen and Procrit). All three of the drugs are made by Amgen Inc., although Procrit is

Can Generic Biologics Be Approved Through an Abbreviated Process?  -  Mar 20, 2007
Atlantic Information Services, Inc.,For example, Eprex (epoetin alfa), the European version of Johnson & Johnson's Procrit, was linked to pure red cell aplasia, a potentially fatal blood

Amgen to Participate in Oncologic Drugs Advisory Committee in May  -  Mar 1, 2007
PharmaLive.com (press release),EPOGEN(R) (Epoetin alfa) is indicated for the treatment of anemia associated with CKD, for patients on dialysis. The dosing instructions recommend targeting

Amgen to participate in Oncologic Drugs Advisory Committee in May  -  Mar 1, 2007
SpiritIndia,EPOGEN® (Epoetin alfa) is indicated for the treatment of anemia associated with CKD, for patients on dialysis. The dosing instructions recommend targeting

Amgen to Participate in Oncologic Drugs Advisory Committee in May  -  Feb 28, 2007
Business Wire (press release),EPOGEN ® (Epoetin alfa) is indicated for the treatment of anemia associated with CKD, for patients on dialysis. The dosing instructions recommend targeting

W. Thomas Amick Appointed Chairman of Discovery Labs' Board of ...  -  Mar 14, 2007
PharmaLive.com (press release),...as Vice President of the Ortho Biotech Oncology Franchise, he launched Procrit(r) (epoetin alfa) and built J&J's oncology franchise into one of the most

Ortho Biotech revises prescribing information for Procrit anemia drug  -  Mar 10, 2007
SpiritIndia,Ortho Biotech Products, LP revised the label for PROCRIT® (Epoetin alfa), acting upon guidance from the US Food and Drug Administration (FDA) to revise

Amgen shares cheap amid anemia drug woes  -  Mar 1, 2007
San Jose Mercury News,Amgen began selling Epogen, known clinically as epoetin alfa, or EPO, in 1989. It stimulates red-blood cell production and has reduced the need for blood

AMGEN backing is risky business  -  Feb 25, 2007
Long Beach Press-Telegram,AMGEN is a cutting edge biotech company that in 1991 went public with a drug called Epogen (Epoetin alfa), known on the cycling street as EPO, that has been

SCCM: Epoetin Alfa Reduces Death Risk For Critically Ill Trauma ...  -  Feb 19, 2007
MedPage Today,19 -- In critically ill trauma patients, recombinant epoetin alfa reduces mortality by 48%, according to the most recent in a series of studies of the

Off-Label Use of Aranesp Linked to Increased Mortality Risk  -  Feb 20, 2007
Medscape (subscription)The study findings may apply to other ESAs such as epoetin alfa (Epogen, made by Amgen; Procrit, made by Ortho Biotech) according to an alert sent Friday

Higher hemoglobin targets linked to increased mortality risk in ...  -  Feb 5, 2007
TheHeart.Org,They add that although treatment with ESAs, such as epoetin alfa and beta and darbepoetin alfa, has been linked to improved exercise capacity and cognition

Study Fails to Demonstrate Effectiveness of Aranesp® in Anemia of ...  -  Jan 31, 2007
Cancer Consultants (press release),Medications such as Procrit® (epoetin alfa) and Aranesp® (darbepoetin alfa) stimulate the body to produce more red blood cells, ultimately reducing anemia

Aranesp Data Eclipse Amgen's Fourth-Quarter Revenue Growth  -  Jan 26, 2007
BioWorld Online,Sales of Epogen (epoetin alfa), which is approved for anemia associated with chronic renal failure in dialysis patients, totaled $661 million,

Treatment of Anemia in Chronic Kidney Disease  -  18 Jan 2007
Medscape (subscription)The transition from epoetin alfa to darbepoetin alfa therapy is usually uncomplicated. The approximate conversion is 200 IU of epoetin alfa to 1 mcg of

Anemia Drug Helpful in Patients with Hepatitis C  -  18 Jan 2007
PakTribune.com,Dieterich, from Mount Sinai School of Medicine, New York, and colleagues evaluated the efficacy of once-weekly doses of epoetin alfa in alleviating anemia

Medicare reimbursement policy for erythropoietin in ESRD flawed  -  Jan 15, 2007
TheHeart.Org,Boston, MA - In 2005, epoetin alfa for the treatment of anemia in end-stage renal disease (ESRD) was the highest-expenditure drug in all of Medicare Part B,

Roche Offers The FDA Additional Mircera Data  -  Jan 15, 2007
Medical News Today (press release),This included treating anaemia in previously untreated patients and maintaining haemoglobin (Hb) after conversion from epoetin alfa/beta or darbepoetin alfa

Steroids, The Truth  -  Jan 14, 2007
SportingNews.comAnabolic steroids are slowly being replaced by synthetic protein hormones (such as epoetin alfa) that selectively stimulate growth of blood cell precursors.

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional